Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective

BRESER Study Demonstrates Real-World Efficacy and Safety of Lupin's Ranibizumab Biosimilar (Ranieyes) - Video

Published On 2025-04-11T11:24:39+05:30  |  Updated On 11 April 2025 1:33 PM IST
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Overview

Ranieyes is the Ranibizumab Biosimilar which is an Indian Ranibizumab Biosimilar manufactured by Lupin Ltd & approved in India for various indications such as retinal vein occlusion (RVO), neovascular age-related macular degeneration (nAMD), myopic macular neovascularization (MNV), and Diabetic macular edema (DME). Ranieyes is an anti-VEG intravitreal injection available in the Indian market since 2021. It has been developed as a biosimilar to reference product Lucentis and it has been found to be safe and well tolerated, biosimilarity being demonstrated through quality/analytical & pragmatic clinical trial studies.

Recently, the BRESER Study, by Dr. Ashish Sharma et. al, has been published in the Journal of Vitreo Retinal Diseases, a peer-reviewed journal of the American Society of Retina Specialists (ASRS).

BRESER Study is a real-world, multicenter, uncontrolled, observational study across 7 eye care centers in India.

A total of 474 ranibizumab biosimilar injections were administered to 268 eyes of 254 patients. The study included patients who received at least one 0.5 mg IVT injection of Ranieyes to evaluate its effectiveness and safety. The treatment was given for diabetic macular edema (DME) (n = 112), macular neovascularization (MNV) (n = 92), retinal vein occlusion (RVO) (n = 54), cystoid macular edema (CME) (n = 4), and proliferative diabetic retinopathy (PDR) with vitreous hemorrhage (n = 6). The mean follow-up duration was 7.7 ± 5.4 weeks.

The results revealed findings which include:

  • Significant improvement in mean logMAR BCVA (Best-Corrected Visual Acuity) (±SD) was observed from baseline to the last follow-up as follows:
    • In diabetic macular edema (DME) cases, improvement was observed from 0.77 ± 0.37 (6/36) to 0.43 ± 0.25 (6/15)
    • In macular neovascularization (MNV) cases, improvement was recorded from 0.95 ± 0.53 (6/60) to 0.59 ± 0.42 (6/24)
    • In retinal vein occlusion (RVO) cases, improvement was noted from 0.83 ± 0.40 (6/45) to 0.44 ± 0.32 (6/15).
    • In PDR (Proliferative Diabetic Retinopathy) cases with vitreous haemorrhage, mean logMAR BCVA improved from 0.71 ± 0.54 (6/30) to 0.28 ± 0.37 (6/12), though this change was not statistically significant.
  • Significant reductions in central subfield thickness (CST) were noted:
    • The CST improved significantly overall (z = −13.3; r = −0.8) and in the DME group (z = −8.3; r = −0.8), MNV group (z = −7.8; r = −0.8), and RVO group.
    • In eyes with PDR and a vitreous hemorrhage, the overall mean CST at baseline was 341.6 ± 183.7 μm, improving to 229.5 ± 25.3 μm.
    • In cystoid macular edema (CME) cases, mean CST decreased from 325.5 ± 50.9 μm to 251 ± 65 μm, but the difference was not statistically significant.
  • The study noted significant improvements in BCVA and CST in terms of efficacy, while none of the seven study sites reported inflammation, vasculitis, vision loss, or other systemic drug-related adverse events.
  • The findings of this preliminary real-world study corroborate the clinical efficacy and safety of Ranieyes as a ranibizumab biosimilar across the approved indications, based on clinical evidence.

Today we have Dr. Ashish Sharma with us we will discuss some questions related to the study:

  1. How common are retinal diseases like diabetic macular edema and macular neovascularization?
  2. How do the BCVA and CST improvements seen in the BRESER study reflect in daily practice?
  3. Advice for young ophthalmologist on how to approach the use of biosimilars like Ranieyes
  4. How do biosimilars like Ranieyes help in making treatment more affordable for patients in India?
  5. Are more Indian real-world studies like BRESER important for doctors?

Reference:

1) Sharma A, Holz FG, Kumar N, et al. Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study. Journal of VitreoRetinal Diseases. 2025;0(0). doi:10.1177/24741264251322213

Speakers

Dr Ashish Sharma

Dr Ashish Sharma MBBS, MS Ophthalmology. He completed a clinical retina and research fellowship at the University of California, Irvine, USA. Dr. Ashish Sharma is a Consultant Retina & Retinal Research at Lotus Eye Hospital and Institute. With 18 years of experience, his specialties include Diabetic Retinopathy, ARMD, and Vein Occlusions.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok